Tremelimumab for the treatment of malignant mesothelioma.
about
Tremelimumab: research and clinical developmentNovel immunotherapy clinical trials in malignant pleural mesothelioma.T cell exhaustion: from pathophysiological basics to tumor immunotherapy.Promising investigational drug candidates in phase I and phase II clinical trials for mesothelioma.CTLA-4 in mesothelioma patients: tissue expression, body fluid levels and possible relevance as a prognostic factor.Immunotherapy advances for mesothelioma treatment.Putative cancer stem cells may be the key target to inhibit cancer cell repopulation between the intervals of chemoradiation in murine mesothelioma.
P2860
Q26752822-50B6DF65-9B4D-4672-8C7A-CD12F97A2400Q33871577-F52FE458-BAB3-41C0-AE55-3FC5E80CFE43Q39078341-ABE6DF54-CBED-491C-94F5-A97AF8A78809Q39415827-346F6594-2A30-4B9F-82C6-950116D5C70FQ39748066-25BCD31D-BBC1-447E-8BBD-B105894FCFD1Q51823843-FFF53F9B-F562-4E83-A286-8643ECF456F4Q52560709-B2064218-923D-4B10-9296-EF03825B5DA6
P2860
Tremelimumab for the treatment of malignant mesothelioma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Tremelimumab for the treatment of malignant mesothelioma.
@en
type
label
Tremelimumab for the treatment of malignant mesothelioma.
@en
prefLabel
Tremelimumab for the treatment of malignant mesothelioma.
@en
P2093
P2860
P1476
Tremelimumab for the treatment of malignant mesothelioma.
@en
P2093
Alice Guazzelli
Marija Krstic-Demonacos
Michelle Hussain
P2860
P304
P356
10.1517/14712598.2015.1116515
P407
P577
2015-11-11T00:00:00Z